CAR-T clinical trial puts refractory B-ALL patient in complete remission at Lu Daopei Hospital

Undoubtedly, the CAR-T clinical trial opens a new avenue for relapsed/refractory leukaemia patients.

Junaid, 19, was diagnosed with "acute B lymphocytic leukaemia" after several tests in a Pakistani hospital for recurrent fever. After almost 4 years of treatment, the acute B lymphoblastic leukaemia relapsed. Chemotherapy was continued at the local hospital, but the cancer cells continued to grow. After hearing from Maisha's father about the successful treatment of Maisha (a similar patient cured at Lu Daopei Hospital), he tried to come to China to find hope.

Junaid was admitted to Lu Daopei Hospital on 26 March 2018. His bone marrow morphology: leukaemia cells (proto-juvenile lymphocytes) were 69%, and cranial nuclear magnetic resonance showed abnormal signal shadows of bilateral ventricles. The white blood cell count was extremely low, and there was a concomitant lung infection. Dr Junfang Yang and her team made an overall assessment, and their decision is to start anti-infection treatment first, then temperature control. If the lung infection is stable, Junaid will be enrolled in the CD19 + CD22 double CAR-T clinical trial.

On 24 April 2018, Junaid received the CD19 + CD22 double CAR-T infusion. During the cytokine response period, the patient developed a high fever, fatigue and other discomforts, which improved after prompt and urgent treatment and the active cooperation of our medical team.

On 9 May 2018, 15 days after the CAR-T infusion, the bone marrow test result showed that he had achieved complete remission (CR). According to the plan, allogeneic haematopoietic stem cell transplantation is being actively prepared. The success of this dual CAR-T is the foundation for allogeneic haematopoietic stem cell transplantation. It has given Junaid new hope.

Junaid is fully HLA compatible with his brother, who has completed the donor screening. 1 month after Junaid's CAR-T infusion, the minimal residual disease (MRD) in vivo was 0, indicating that the CAR-T clinical trial was successful for him, and he was discharged and prepared for allogeneic haematopoietic stem cell transplantation.

Chinese blood organisation is the patient's solid support

Junaid is RH negative blood type, which is a rare blood type. He accepted free blood donations from "Lang Fang rare blood type alliance" many times during his hospitalisation. Meanwhile, Junaid received help from many Chinese friends, which strengthened his confidence to stay in China for treatment.

Benefiting patients with China's most advanced technology

The Dual CAR technology used for Junaid is the most advanced CAR-T technology.

Lu Daopei Hospital cooperated with Hebei Senlang Biotechnology Co., Ltd start-up (CD19 + CD22 double CAR-T) clinical trial for the treatment of refractory/relapsed B-ALL. The new technology has successfully saved many patients. Lu Daopei Hospital is committed to academic research and clinical treatment to alleviate patients' pain and provide better treatment. The needs of the patients are what keep us going.